Medical Patent News

RSS

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

Genentech asserts SPC non-infringement of products in Europe, seeks response from PDL

PDL BioPharma, Inc. announced today it has received a facsimile letter from Genentech asserting that Avastin, Herceptin, Lucentis and Xolair (the Genentech Products) do not infringe supplementary protection certificates granted by various countries in Europe to PDL and is seeking a response from PDL to these assertions.

16 Aug 2010

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.

13 Aug 2010

Sandata announces acquisition of Medical Management Technology Group's customer base

Sandata Technologies, LLC, a leading nationwide provider of information technology solutions to the home healthcare and social services communities today announced the acquisition of all of the home healthcare agency contracts of Medical Management Technology Group, Inc. in connection with the settlement of a patent infringement lawsuit.

13 Aug 2010

Endologix responds to Bard Peripheral Vascular's patent infringement lawsuit

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular Graft" patent (U.S. Patent No. 6,436,135).

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office has allowed claims in a patent application (US Serial No. 12/550,579) derived from the "Tuschl III" patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.

11 Aug 2010

GenSpera issued additional patent for G-202

GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Immunomedics receives additional patent for CD74 target

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.

11 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Detection of malignant melanoma, the most serious type of skin cancer, will soon be quicker and easier thanks to the work of researchers at Missouri University of Science and Technology.The research, which is funded by the National Institutes of Health, recently received a patent titled "Automatic Detection of Critical Dermoscopy Features for Malignant Melanoma Diagnosis." The patent applies to a method for computer-aided analysis of photographs of skin lesions to detect the cancer. Melanoma can be cured if it is diagnosed early enough.

11 Aug 2010

Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.

11 Aug 2010

CareView files patent for innovative technology to prevent decubitus ulcers

CareView Communications, Inc. ("CareView" or the "Company"), an information technology provider to the healthcare industry, announced that it has filed a new patent with the United States Patent and Trademark Office to cover an innovative technology that will assist hospitals and other medical facilities in their efforts to prevent decubitus ulcers or "bed sores" experienced by patients. CareView's new product covered by the pending patent uses the CareView System monitoring system to ensure timely patient movement which assists caregivers in the prevention and treatment of bed sores.

10 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

Akonni Biosystems receives patent for TruTip Extraction Kits

Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.

6 Aug 2010

Medical Patent News

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Genentech asserts SPC non-infringement of products in Europe, seeks response from PDL

Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation

Sandata announces acquisition of Medical Management Technology Group's customer base

Endologix responds to Bard Peripheral Vascular's patent infringement lawsuit

Intellect Neurosciences receives patent for insulin sensitizer drugs

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Repros receives US patent for Androxal

Silence Therapeutics receives patent for RNA silencing method

GenSpera issued additional patent for G-202

Entelos receives patent for PhysioLab virtual patient technology

Immunomedics receives additional patent for CD74 target

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Stoecker and Associates develops new software for early diagnosis of malignant melanoma

Clarient receives patent for Mammostrat breast cancer prognostic test

CareView files patent for innovative technology to prevent decubitus ulcers

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Akonni Biosystems receives patent for TruTip Extraction Kits

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News